4.7 Editorial Material

Reducing QT liability and proarrhythmic risk in drug discovery and development

Related references

Note: Only part of the references are listed.
Article Pharmacology & Pharmacy

A framework to assess the translation of safety pharmacology data to humans

Jean-Pierre Valentin et al.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)

Article Pharmacology & Pharmacy

Beyond the safety assessment of drug-mediated changes in the QT interval… what's next?

Michael K. Pugsley et al.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)

Article Pharmacology & Pharmacy

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays

Elena S. Trepakova et al.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)

Article Pharmacology & Pharmacy

Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development?

Mark Holbrook et al.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2008)

Article Cardiac & Cardiovascular Systems

Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death

ML De Bruin et al.

EUROPEAN HEART JOURNAL (2005)

Article Public, Environmental & Occupational Health

Drugs, QT interval prolongation and ICH E14 - The need to get it right

RR Shah

DRUG SAFETY (2005)